Alva’s Omega Diagnostics in Omicron test success

Alva-based Omega Diagnostics Group said on Tuesday that analysis from clinical samples shows that its Covid-19 antigen test performs with “the same high accuracy” on the Omicron variant.

“Omega … has been notified by its technology partner Mologic Ltd that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT COVID-19 antigen test.”

Omega Diagnostics CEO Colin King said: “We are very pleased be in a position to confirm that the VISITECT COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants.

“We remain encouraged by emerging commercial opportunities for our VISITECT COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use.” 

About the Author

Mark McSherry
Dalriada Media LLC sites are edited by veteran news journalist Mark McSherry, a former staff editor and reporter with Reuters, Bloomberg and major newspapers including the South China Morning Post, London's Sunday Times and The Scotsman. McSherry's journalism has also appeared in The Washington Post, The Guardian, The Independent, The New York Times, London's Evening Standard and Forbes. McSherry is also a professor of journalism and communication arts in universities and colleges in New York City. Scottish-born McSherry has an MBA from the University of Edinburgh and a Certificate in Global Affairs from New York University.